Symbols / /CNSP
/CNSP Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
—
Low
—
High
—
Mean
—
- CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan Wed, 11 Mar 2026 12
- Understanding Momentum Shifts in (CNSP) - Stock Traders Daily ue, 03 Mar 2026 20
- Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan Mon, 02 Mar 2026 13
- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance Wed, 26 Mar 2025 07
- CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Stocktwits Fri, 16 May 2025 13
- CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - The Globe and Mail Fri, 18 Jul 2025 07
- Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan ue, 17 Feb 2026 08
- CNS Pharmaceuticals shares tumble after clinical trial results - Investing.com ue, 25 Mar 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Fri, 16 Feb 2024 17
- CNSP - CNS Pharmaceuticals Latest Stock News & Market Updates - Stock Titan Wed, 17 Dec 2025 08
- CNSP stock touches 52-week low at $0.08 amid sharp annual decline - Investing.com Wed, 19 Feb 2025 08
- CNS Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance Mon, 03 Jun 2024 07
- Brain cancer drug developer taps new CEO with global track record - Stock Titan Wed, 17 Dec 2025 08
- CNSP Stock Touches 52-Week Low at $0.81 Amid Steep Decline - Investing.com ue, 30 Jul 2024 07
- CNS Pharmaceuticals (NASDAQ: CNSP) trims Q3 loss, cash funds operations into 2026 - Stock Titan Mon, 17 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.84M | -18.83M | -15.26M | -14.47M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.86M | -18.85M | -15.27M | -14.50M |
| ReconciledDepreciation | 3.31K | 4.13K | 11.76K | 13.07K |
| EBITDA | -14.84M | -18.83M | -15.26M | -14.47M |
| EBIT | -14.84M | -18.84M | -15.27M | -14.49M |
| NetInterestIncome | 44.14K | 13.88K | -7.03K | -9.29K |
| InterestExpense | 16.12K | 13.80K | 7.03K | 9.29K |
| InterestIncome | 60.26K | 27.69K | 0.00 | |
| NormalizedIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.86M | -18.85M | -15.27M | -14.50M |
| TotalExpenses | 14.90M | 18.87M | 15.27M | 14.49M |
| TotalOperatingIncomeAsReported | -14.90M | -18.87M | -15.27M | -14.49M |
| DilutedAverageShares | 117.80K | 207.00 | 53.00 | 31.00 |
| BasicAverageShares | 117.80K | 207.00 | 53.00 | 31.00 |
| DilutedEPS | -126.13 | -91.07K | -288.19K | -467.59K |
| BasicEPS | -126.13 | -91.07K | -288.19K | -467.59K |
| DilutedNIAvailtoComStockholders | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeCommonStockholders | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeIncludingNoncontrollingInterests | -14.86M | -18.85M | -15.27M | -14.50M |
| NetIncomeContinuousOperations | -14.86M | -18.85M | -15.27M | -14.50M |
| PretaxIncome | -14.86M | -18.85M | -15.27M | -14.50M |
| NetNonOperatingInterestIncomeExpense | 44.14K | 13.88K | -7.03K | -9.29K |
| InterestExpenseNonOperating | 16.12K | 13.80K | 7.03K | 9.29K |
| InterestIncomeNonOperating | 60.26K | 27.69K | 0.00 | |
| OperatingIncome | -14.90M | -18.87M | -15.27M | -14.49M |
| OperatingExpense | 14.90M | 18.87M | 15.27M | 14.49M |
| ResearchAndDevelopment | 9.29M | 14.10M | 9.30M | 9.81M |
| SellingGeneralAndAdministration | 5.61M | 4.77M | 5.97M | 4.68M |
| GeneralAndAdministrativeExpense | 5.61M | 4.77M | 5.97M | 4.68M |
| OtherGandA | 5.61M | 4.77M | 5.97M | 4.68M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 117.80K | 207.00 | 53.00 | 31.00 |
| ShareIssued | 117.80K | 207.00 | 53.00 | 31.00 |
| TotalDebt | 326.07K | 300.81K | 409.97K | 387.79K |
| TangibleBookValue | 6.18M | -4.43M | 8.13M | 6.16M |
| InvestedCapital | 6.50M | -4.13M | 8.54M | 6.55M |
| WorkingCapital | 6.13M | -4.54M | 7.64M | 4.88M |
| NetTangibleAssets | 6.18M | -4.43M | 8.13M | 6.16M |
| CommonStockEquity | 6.18M | -4.43M | 8.13M | 6.16M |
| TotalCapitalization | 6.18M | -4.43M | 8.13M | 6.16M |
| TotalEquityGrossMinorityInterest | 6.18M | -4.43M | 8.13M | 6.16M |
| StockholdersEquity | 6.18M | -4.43M | 8.13M | 6.16M |
| RetainedEarnings | -84.42M | -69.57M | -50.72M | -35.44M |
| AdditionalPaidInCapital | 90.60M | 65.13M | 58.85M | 41.60M |
| CapitalStock | 1.41K | 2.00 | 1.62K | 949.00 |
| CommonStock | 1.41K | 2.00 | 1.62K | 949.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.52M | 6.13M | 4.92M | 2.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 2.52M | 6.13M | 4.92M | 2.59M |
| CurrentDebtAndCapitalLeaseObligation | 326.07K | 300.81K | 409.97K | 387.79K |
| CurrentDebt | 326.07K | 300.81K | 409.97K | 387.79K |
| CurrentNotesPayable | 326.07K | 300.81K | 409.97K | 387.79K |
| PayablesAndAccruedExpenses | 2.20M | 5.83M | 4.51M | 2.21M |
| CurrentAccruedExpenses | 828.39K | 224.95K | ||
| Payables | 3.68M | 1.98M | ||
| AccountsPayable | 3.68M | 1.98M | ||
| TotalAssets | 8.70M | 1.70M | 13.05M | 8.76M |
| TotalNonCurrentAssets | 42.44K | 109.68K | 488.47K | 1.28M |
| NonCurrentPrepaidAssets | 36.43K | 104.75K | 482.81K | 929.69K |
| NonCurrentDeferredAssets | 0.00 | 334.14K | ||
| NetPPE | 6.00K | 4.93K | 5.66K | 16.11K |
| CurrentAssets | 8.66M | 1.59M | 12.56M | 7.48M |
| OtherCurrentAssets | 1.29M | 839.59K | 2.51M | 2.47M |
| CurrentDeferredAssets | 20.64K | 202.86K | 0.00 | |
| PrepaidAssets | 2.51M | 2.47M | ||
| Receivables | 882.54K | 0.00 | ||
| AccountsReceivable | 882.54K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 6.46M | 548.72K | 10.06M | 5.00M |
| CashAndCashEquivalents | 6.46M | 548.72K | 10.06M | 5.00M |
| CashFinancial | 548.72K | 10.06M | 5.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.12M | -14.14M | -10.56M | -13.54M |
| RepaymentOfDebt | -300.81K | -438.73K | -427.70K | -477.49K |
| IssuanceOfCapitalStock | 23.38M | 2.32M | 16.04M | 4.65M |
| CapitalExpenditure | -4.19K | -3.90K | -4.42K | -5.75K |
| InterestPaidSupplementalData | 13.60K | 13.80K | 8.09K | 9.77K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 6.46M | 548.72K | 10.06M | 5.00M |
| BeginningCashPosition | 548.72K | 10.06M | 5.00M | 14.04M |
| ChangesInCash | 5.91M | -9.51M | 5.05M | -9.03M |
| FinancingCashFlow | 23.03M | 4.64M | 15.61M | 4.51M |
| CashFlowFromContinuingFinancingActivities | 23.03M | 4.64M | 15.61M | 4.51M |
| NetOtherFinancingCharges | -66.75K | -202.86K | ||
| ProceedsFromStockOptionExercised | 21.32K | 2.96M | 2.73K | 332.75K |
| NetCommonStockIssuance | 23.38M | 2.32M | 16.04M | 4.65M |
| CommonStockIssuance | 23.38M | 2.32M | 16.04M | 4.65M |
| NetIssuancePaymentsOfDebt | -300.81K | -438.73K | -427.70K | -477.49K |
| NetShortTermDebtIssuance | -300.81K | -438.73K | -427.70K | -477.49K |
| ShortTermDebtPayments | -300.81K | -438.73K | -427.70K | -477.49K |
| NetLongTermDebtIssuance | -477.49K | |||
| LongTermDebtPayments | -477.49K | |||
| InvestingCashFlow | -4.19K | -3.90K | -4.42K | -5.75K |
| CashFlowFromContinuingInvestingActivities | -4.19K | -3.90K | -4.42K | -5.75K |
| NetPPEPurchaseAndSale | -4.19K | -3.90K | -4.42K | -5.75K |
| PurchaseOfPPE | -4.19K | -3.90K | -4.42K | -5.75K |
| OperatingCashFlow | -17.11M | -14.14M | -10.56M | -13.54M |
| CashFlowFromContinuingOperatingActivities | -17.11M | -14.14M | -10.56M | -13.54M |
| ChangeInWorkingCapital | -3.69M | 3.70M | 3.16M | -780.02K |
| ChangeInPayablesAndAccruedExpense | -3.63M | 1.32M | 2.30M | 740.26K |
| ChangeInAccruedExpense | 603.44K | -294.86K | ||
| ChangeInPayable | 1.70M | 1.04M | ||
| ChangeInAccountPayable | 1.70M | 1.04M | ||
| ChangeInPrepaidAssets | -59.97K | 2.38M | 860.45K | -1.52M |
| OtherNonCashItems | 596.30K | |||
| StockBasedCompensation | 838.96K | 1.01M | 1.20M | 1.72M |
| AssetImpairmentCharge | 0.00 | 334.14K | 0.00 | |
| DepreciationAmortizationDepletion | 3.31K | 4.13K | 11.76K | 13.07K |
| DepreciationAndAmortization | 3.31K | 4.13K | 11.76K | 13.07K |
| Depreciation | 3.31K | 4.13K | 11.76K | 13.07K |
| OperatingGainsLosses | -190.00 | 498.00 | 3.11K | |
| GainLossOnSaleOfPPE | -190.00 | 498.00 | 3.11K | 0.00 |
| NetIncomeFromContinuingOperations | -14.86M | -18.85M | -15.27M | -14.50M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for /CNSP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|